| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenues | 581 | 18,306 | 6,437 | 49,412 |
| Research and development | 28,142 | 27,084 | 26,006 | 27,732 |
| General and administrative | 7,992 | 9,077 | 10,059 | 11,049 |
| Impairment of long-lived assets | 0 | 0 | - | - |
| Total operating expenses | 36,134 | 36,161 | 36,065 | 38,781 |
| (loss) income from operations | -35,553 | -17,855 | -29,628 | 10,631 |
| Interest income | 355 | 386 | 309 | 129 |
| Other income (expense), net | 107 | -2,490 | -1,159 | - |
| (loss) income before income taxes | -35,091 | -19,959 | -30,478 | 10,760 |
| Income tax (benefit) expense | -161 | 27 | 119 | 88 |
| Net (loss) income | -34,930 | -19,986 | -30,597 | 10,672 |
| Net income allocated to participating securities | 0 | - | - | 1,287 |
| Net (loss) income available to common stockholders | -34,930 | - | - | 9,385 |
| Net (loss) income per share, basic (in dollars per share) | -0.11 | -0.08 | -0.14 | 0.05 |
| Net (loss) income per share, diluted (in dollars per share) | -0.11 | -0.08 | -0.14 | 0.04 |
| Shares used in computing diluted net (loss) income per share (in shares) | 304,268,000 | 256,950,000 | 220,269,000 | 214,325,000 |
| Weighted average number of common shares outstanding - basic (in shares) | 304,268,000 | 256,950,000 | 220,269,000 | 208,345,000 |
SANGAMO THERAPEUTICS, INC (SGMO)
SANGAMO THERAPEUTICS, INC (SGMO)